Peptide · developed by MBX Biosciences
MBX 2109 (also known as PPL 2717) is a once-weekly subcutaneously injected investigational agent supplied as a lyophilized vial for reconstitution. It is studied in hypoparathyroidism and in healthy participants.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06531941 | Phase 2 | Hypoparathyroidism | Active not recruiting | MBX |
| NCT05158335 | Phase 1 | Healthy | Completed | MBX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HypoparathyroidismHealthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the MBX page.
See MBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MBX catalysts and pipeline →